Monday, October 5, 2026

Intel +240%, AMD +112%: AI Inference Boom Rewards CPU Makers as Nvidia Stalls at +15%

Intel, AMD, and Micron are dramatically outperforming Nvidia in 2026, with gains of 240%, 112%, and 162% respectively against Nvidia's +15%. AI inference demand is driving the divergence: Nvidia's dominance is already priced in, while upstream memory suppliers and newly competitive CPU vendors are still re-rating. AMD doubling its server CPU TAM forecast signals direct competitive pressure on Nvidia's adjacent markets.

LM Salvado

May 12, 2026

Intel +240%, AMD +112%: AI Inference Boom Rewards CPU Makers as Nvidia Stalls at +15%
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Intel stock has surged 240% year-to-date in 2026.1 AMD is up 112%. Micron Technology has gained 162%.1 Nvidia, the dominant AI chip maker, has returned just 15%.1

The divergence reflects how AI infrastructure spending flows through the semiconductor supply chain. Nvidia's GPU dominance is established and already priced into its valuation. The market is now repricing companies at the edges of Nvidia's ecosystem.

AI inference — running trained models to generate outputs — demands different hardware than training. Training favors Nvidia's high-end GPUs. Inference rewards efficiency, scale, and lower cost-per-query. CPUs from Intel and AMD increasingly compete on inference workloads, particularly where GPU-level parallelism is unnecessary.

AMD doubled its server CPU total addressable market forecast, signaling competitive pressure on Nvidia's adjacent server business.1 That revision implies AMD sees real demand for CPU-based inference, not theoretical opportunity.

Micron's 162% gain reflects its position as a critical supplier to both camps.1 High-bandwidth memory is essential regardless of whether a workload runs on a GPU or CPU. Micron ships to Nvidia, Intel, and the hyperscalers building AI infrastructure. Its gains reflect broad AI infrastructure spending, not a single architecture bet.

The pattern mirrors previous infrastructure cycles. Dominant platform vendors often underperform once their position is priced in. Re-rating happens upstream — in components and in adjacent competitors gaining share.

Nvidia's +15% is not a decline. It reflects a stock already valued for dominance. Intel's +240% reflects a market repricing a company that spent years losing ground and has found renewed relevance in an inference-heavy landscape.

The thesis will be tested in IDC and Gartner server market share reports through end of 2026.1 If AMD's CPU share gains materialize in quarterly data, the bifurcation holds. If Nvidia extends its GPU lead into inference, the Intel and AMD re-rating may prove temporary.

For now, the semiconductor market is voting that AI infrastructure build-out benefits everyone — but that Nvidia's upside is already spent.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com